Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Regenxbio Inc (NASDAQ: RGNX) closed at $7.80 in the last session, up 11.43% from day before closing price of $7.00. In other words, the price has increased by $11.43 from its previous closing price. On the day, 1.57 million shares were traded. RGNX stock price reached its highest trading level at $7.88 during the session, while it also had its lowest trading level at $6.8.
Ratios:
We take a closer look at RGNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.69 and its Current Ratio is at 2.69. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 30 ’24 when VITTAL VASISTA bought 20,041 shares for $7.41 per share.
KARABELAS ARGERIS N sold 10,000 shares of RGNX for $101,052 on Oct 01 ’24. The Director now owns 11,286 shares after completing the transaction at $10.11 per share. On Sep 03 ’24, another insider, KARABELAS ARGERIS N, who serves as the Director of the company, sold 10,000 shares for $11.56 each. As a result, the insider received 115,588 and left with 11,286 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 390671584 and an Enterprise Value of 297704864. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.69 while its Price-to-Book (P/B) ratio in mrq is 1.49. Its current Enterprise Value per Revenue stands at 3.573 whereas that against EBITDA is -1.384.
Stock Price History:
The Beta on a monthly basis for RGNX is 1.29, which has changed by -0.6534873 over the last 52 weeks, in comparison to a change of 0.07465422 over the same period for the S&P500. Over the past 52 weeks, RGNX has reached a high of $23.14, while it has fallen to a 52-week low of $5.62. The 50-Day Moving Average of the stock is 6.75%, while the 200-Day Moving Average is calculated to be -23.08%.
Shares Statistics:
According to the various share statistics, RGNX traded on average about 1.16M shares per day over the past 3-months and 969310 shares per day over the past 10 days. A total of 49.55M shares are outstanding, with a floating share count of 45.20M. Insiders hold about 9.75% of the company’s shares, while institutions hold 86.28% stake in the company. Shares short for RGNX as of 1740700800 were 6280862 with a Short Ratio of 5.41, compared to 1738281600 on 6408552. Therefore, it implies a Short% of Shares Outstanding of 6280862 and a Short% of Float of 16.580000000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
